S-1/A: MetaVia Inc. Launches Public Offering to Fund Clinical Development

MetaVia Inc. announced a public offering of Class A and Class B Units to raise approximately $6.0 million for working capital and clinical development of its cardiometabolic drug candidates, despite ongoing net losses and a 'going concern' warning.

Summary

• MetaVia Inc. is offering up to 919,681 Class A Units, each consisting of one share of common stock, 1.5 Series C Common Warrants, and 1.5 Series D Common Warrants, at an assumed public offering price of $8.155 per unit.
• Alternatively, certain purchasers may buy Class B Units, each consisting of one pre-funded warrant, 1.5 Series C Common Warrants, and 1.5 Series D Common Warrants, at a purchase price of $8.154 per unit.
• The offering aims to raise estimated net proceeds of approximately $6.0 million (or $7.0 million if the over-allotment option is fully exercised) for working capital and general corporate purposes, including the clinical development of DA-1726 for obesity.
• The company reported a net loss of $11.0 million and an accumulated deficit of $146.9 million as of September 30, 2025, and expects cash and cash equivalents to be approximately $10.3 million with no outstanding debt as of December 31, 2025.
• Management believes the existing cash, combined with the expected net proceeds from this offering, will fund operations into the third quarter of 2026.
• Positive top-line 16-week results were announced in December 2024 for the Phase 2a clinical trial of Vanoglipel (DA-1241) in patients with presumed MASH, showing statistically significant reductions in ALT levels and improvements in CAP and FAST scores.
• Positive top-line data was announced on January 5, 2026, for the Phase 1 MAD Part 2 non-titrated 48 mg Cohort 5 clinical trial of DA-1726 for obesity, demonstrating statistically significant weight reduction (6.1% at Day 26, 9.1% at Day 54) and waist circumference reduction, alongside favorable safety and glucose control.
• The company regained compliance with Nasdaq's minimum bid price requirement on December 19, 2025, after its common stock traded at or above $1.00 for 10 consecutive business days.

Sentiment

Score: 6

Explanation: The sentiment is cautiously optimistic. While the company has reported strong positive clinical data for its lead candidates and is actively addressing its financial needs through a public offering, the 'going concern' warning and recurring net losses present significant financial risks. The success of the offering and future clinical milestones are critical for long-term viability.

Positives

• Vanoglipel (DA-1241) Phase 2a trial in MASH achieved its primary efficacy endpoint with statistically significant reductions in ALT levels at weeks 4 and 8 (p = 0.0159 and p = 0.0342, respectively) and near statistical significance at week 16 (p = 0.0506) compared to placebo.
• Vanoglipel (DA-1241) 50 mg showed a statistically significant improvement in the normalization of ALT levels compared to placebo (odds ratio of 10.500, p = 0.0487).
• Vanoglipel (DA-1241) 100 mg and combination therapy with Sitagliptin 100 mg showed significant improvements in CAP score (p=0.0308 and p=0.0452, respectively) and the combination showed a statistically significant reduction in FAST score (p = 0.0416).
• Vanoglipel (DA-1241) 100 mg and combination therapy with Sitagliptin 100 mg showed significant reductions in HbA1c from baseline at Week 16 compared to placebo (p = 0.0179 and p = 0.0050, respectively).
• Vanoglipel (DA-1241) demonstrated a strong safety profile with mostly mild adverse events and no drug-related serious adverse events or discontinuations due to adverse events.
• DA-1726 Phase 1 MAD Part 2 non-titrated 48 mg Cohort 5 clinical trial showed statistically significant weight reduction of 6.1% (14.6 lbs.) at Day 26 and 9.1% (21.2 lbs.) at Day 54 compared to placebo.
• DA-1726 48 mg showed statistically significant waist circumference reduction of 5.8 cm (2.3 inches) at Day 26 and 9.8 cm (3.8 inches) at Day 56 compared to placebo.
• DA-1726 48 mg demonstrated fasted glucose control with a 12.3 mg/dL reduction from baseline in eight weeks, with one prediabetic subject normalizing HbA1c from 6.0% to 5.5%.
• DA-1726 48 mg showed a significant 23.7% reduction in liver stiffness (VCTE) in eight weeks, from 5.9 kPa to 4.5 kPa.
• DA-1726 exhibited a compelling adverse event profile with no treatment-related discontinuations and mild to moderate gastrointestinal adverse events.
• The company regained compliance with Nasdaq's Minimum Bid Price Requirement on December 19, 2025.

Negatives

• The company has incurred net losses since inception and anticipates continued net losses for the foreseeable future.
• A net loss of $11.0 million and an accumulated deficit of $146.9 million were reported as of September 30, 2025.
• The company has experienced negative cash flows from operating activities since inception, with $10.8 million used in operating activities for the nine months ended September 30, 2025.
• There is substantial doubt about the company's ability to continue as a going concern within twelve months from the issuance of the consolidated financial statements.
• The company is dependent on working capital to fund its business plan and requires additional capital, with no current commitments for additional financing.
• Raising additional capital may cause material dilution to existing stockholders, restrict operations, or require relinquishing rights to technologies.
• The company has no experience manufacturing product candidates on a large clinical or commercial scale and relies exclusively on Dong-A as the sole manufacturer for Vanoglipel (DA-1241) and DA-1726, posing supplier risk.

Risks

• Incurring net losses since inception and anticipating continued net losses for the foreseeable future, requiring additional capital.
• Failure to obtain necessary capital on acceptable terms could force delays, limits, reductions, or termination of operations.
• Dependence on working capital to fund the business plan, with additional capital raising potentially causing dilution, restricting operations, or requiring relinquishment of technology rights.
• Future sales, or the perception of future sales, by the company or its securityholders could cause the market price of common stock to decline.
• Adverse global economic conditions could materially affect business, results of operations, financial condition, and liquidity.
• Expending limited resources on a particular product candidate or indication may lead to failure to capitalize on more profitable opportunities.
• Significant payments may be required under the exclusive license agreement with Dong-A, which also mandates Dong-A as the sole manufacturer.
• Inability to obtain regulatory approval for, or successfully commercialize, Vanoglipel (DA-1241) and DA-1726 even with favorable clinical results.
• Preliminary, interim, and top-line data from clinical trials may change as more patient data become available and are subject to audit and verification.
• Results of earlier clinical trials may not be predictive of later-stage clinical trials.
• Product candidates may cause undesirable side effects, delaying or preventing marketing approval, limiting commercial profile, or resulting in negative consequences post-approval.
• Efforts to discover drug candidates beyond current ones may not succeed, and recommended candidates may not begin clinical trials.
• Enrollment and retention of patients in clinical trials is expensive, time-consuming, and difficult due to factors like MASH diagnosis challenges and competition.
• Substantial competition from larger pharmaceutical companies with greater resources and experience.
• Engagement in strategic transactions could impact liquidity, increase expenses, and distract management.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Reliance on collaborative partners (e.g., Dong-A) for development exposes the company to risks regarding resource allocation, intellectual property, and potential termination of agreements.
• Reliance on third-party clinical research organizations (CROs) to conduct preclinical studies and clinical trials, with risks if they fail to meet duties or deadlines.
• Reliance on third parties to manufacture product candidates and drug supplies, with risks related to regulatory compliance, quality assurance, and supply chain disruptions.
• Future acquisitions, mergers, or in-licenses/out-licenses of technology could disrupt business, cause dilution, and harm financial condition.
• Inability to obtain and maintain sufficient intellectual property rights could harm competitive position.
• Inability to protect or practice intellectual property rights globally, especially in countries with weaker IP laws.
• Involvement in lawsuits to protect or enforce intellectual property could be expensive, time-consuming, and unsuccessful.
• Difficulty in protecting trade secrets, which could harm business and competitive position if disclosed or independently developed.
• Dependence on compliance with governmental patent agency requirements for patent protection, with risks of reduction or elimination for non-compliance.
• Intellectual property rights may not address all potential threats to competitive advantage.
• Small number of employees and consultants, with future success dependent on retaining executive officers and attracting qualified personnel.
• Difficulties in managing growth as the organization expands.
• Risks of doing business outside the U.S., including international sales, regulatory changes, and intellectual property enforcement.
• The pharmaceutical industry is highly competitive and subject to rapid technological change, potentially rendering technologies and products obsolete.
• Volatility and substantial fluctuations in the price of common stock, leading to potential losses for stockholders.
• Largest stockholders (Dong-A and Dong-A Holdings) may use significant interests to take actions not supported by other stockholders.
• Status as a controlled company under Nasdaq listing requirements, potentially relying on exemptions from certain corporate governance requirements.
• Provisions in corporate charter documents and Delaware law may make an acquisition more difficult and prevent attempts to replace management.
• Reduced reporting requirements as a smaller reporting company could make common stock less attractive to investors.
• Business and operations may suffer from system failures or other unplanned events, including cybersecurity incidents.
• Inadequate funding of the FDA and other government agencies could hinder timely product development and commercialization.
• Federal legislation and actions by state/local governments may permit reimportation of drugs from foreign countries, adversely affecting operating results.
• Product liability lawsuits could cause substantial liabilities and limit commercialization.
• Relationships with healthcare providers and third-party payors subject to anti-kickback, fraud, and abuse laws, exposing the company to sanctions.
• Subject to U.S. and foreign export/import controls, sanctions, embargoes, anti-corruption, and anti-money laundering laws, with potential for criminal liability.
• Ability to use net operating losses (NOLs) to offset future taxable income may be subject to limitations.
• Tax matters, including changes in corporate tax rates, disagreements with taxing authorities, and new taxes, could impact financial results.
• Immediate and substantial dilution for new investors purchasing securities in this offering, with potential for further dilution from future equity issuances.
• Broad discretion of management in the use of existing cash and offering proceeds, which may not be used effectively.
• No public market for the pre-funded warrants or Common Warrants, limiting their liquidity.
• Public holders may only be able to exercise Common Warrants on a cashless basis if a current and effective prospectus is not maintained.
• The Common Warrants are speculative in nature, with no assurance of market value or profitability of exercise.
• Nominal or no additional funds will be received upon the exercise of pre-funded warrants.
• Holders of pre-funded warrants and Common Warrants generally have no rights as stockholders until exercise.
• Significant holders may be limited in exercising pre-funded warrants or Common Warrants due to beneficial ownership limitations.

Future Outlook

MetaVia Inc. expects its current cash and the net proceeds from this offering to fund operations into the third quarter of 2026. The company plans to finalize the Clinical Study Report for Vanoglipel (DA-1241) Phase 2a in the first half of 2026 and schedule an end-of-Phase 2 meeting with the FDA. For DA-1726, Phase 1 Part 3a and 3b trials are planned to start in the first quarter of 2026, with data readout expected in the fourth quarter of 2026. These titration studies aim to assess the maximum tolerated dose and potentially achieve best-in-class safety and tolerability with dose-dependent weight loss.

Management Comments

• We are currently finalizing the Clinical Study Report on a Phase 2a clinical trial in the United States for Vanoglipel (DA-1241).
• We are currently working to schedule an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for Vanoglipel (DA-1241).
• We are planning to start Phase 1 Part 3a and Part 3b during the 1st quarter of 2026 for DA-1726.
• We expect dose-dependent exploratory weight loss and other early signals in the exploratory endpoints with potential for best-in-class safety and tolerability for DA-1726.
• We expect to complete our financial statements for the year ended December 31, 2025 subsequent to the closing of this offering.

Industry Context

MetaVia operates in the highly competitive clinical-stage biotechnology sector, focusing on cardiometabolic diseases like MASH, obesity, and Type 2 Diabetes Mellitus. The industry is characterized by rapid technological advancements and a strong emphasis on proprietary products. Competitors include major pharmaceutical and biotechnology companies with significantly greater financial and R&D resources, such as Madrigal Pharmaceuticals (MASH), Novo Nordisk (semaglutide), and Eli Lilly (tirzepatide) in the obesity and MASH markets. The company's dual agonist approach for DA-1726 aims to differentiate it in the crowded obesity treatment landscape by increasing energy expenditure in addition to appetite suppression.

Comparison to Industry Standards

• Vanoglipel (DA-1241) is a potential first-in-class GPR119 agonist, differentiating it from the single approved MASH treatment (Madrigal Pharmaceuticals' thyroid hormone receptor beta agonist) and other candidates in development (e.g., GLP1 agonists, FGF21 analogs, farnesoid X receptor agonists).
• DA-1726, a GLP1R and GCGR dual agonist, demonstrated superior body weight loss compared to semaglutide in high-fat diet-induced obese mice in preclinical studies, suggesting potential for best-in-class efficacy among GLP-1 incretins combined with glucagon.
• DA-1726 showed similar glycemic control to semaglutide in obese mice with hyperglycemia but without hypoglycemia risk in overnight fasted normal mice, indicating a potentially safer profile.
• DA-1726's mechanism of increasing energy expenditure through GCGR activation offers a differentiated approach compared to existing approved anti-obesity medications like semaglutide (WEGOVY) and tirzepatide (Zepbound), which primarily focus on appetite suppression.

Corporate Governance

Legal Proceedings

• No action, suit, inquiry, notice of violation, proceeding or investigation pending or threatened against or affecting the Company, any Subsidiary or any of their respective properties which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Public Securities or (ii) could, if there were an unfavorable decision, have or reasonably be expected to result in a Material Adverse Effect.
• Neither the Company nor any Subsidiary, nor to the Company's knowledge, any current director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.
• No investigation by the Commission involving the Company or any current or former director or officer of the Company is pending or contemplated.
• The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.

Related Party Transactions

• Dong-A ST Co., Ltd. and Dong-A Socio Holdings Co., Ltd. are significant stockholders, beneficially owning approximately 76.5% of voting rights as of December 9, 2025.
• The company has an exclusive global license (excluding Republic of Korea) from Dong-A ST for Vanoglipel (DA-1241) and DA-1726, under which Dong-A ST is eligible for regulatory milestone payments of up to $222.0 million for Vanoglipel (DA-1241) and $267.0 million for DA-1726, commercial-based milestone payments, and single-digit royalties on net sales.
• Dong-A ST is the sole manufacturer for the production of Vanoglipel (DA-1241) and DA-1726 under a Shared Services Agreement.
• The company incurred R&D expenses of $0.2 million and $2.6 million for the three and nine months ended September 30, 2025, respectively, under the Shared Services Agreement with Dong-A ST.
• The aggregate amount payable to Dong-A ST under the Shared Services Agreement was $3.3 million as of September 30, 2025, including $2.0 million payable with extended terms (installments in March, June, and September 2026) and $1.3 million in clinical trial accrued liabilities.
• In May 2025, the company closed a private placement offering with Dong-A ST and Dong-A Holdings, receiving gross proceeds of $10.0 million from the issuance of common stock and pre-funded warrants.

Stakeholder Impact

• **Shareholders:** Potential for significant dilution from the current offering and future capital raises. The concentration of ownership by Dong-A and Dong-A Holdings (76.5% voting rights) gives them significant influence over corporate actions, potentially affecting other stockholders' interests. Stock price volatility is a risk.
• **Employees:** Future success depends on retaining executive officers and attracting qualified personnel in a competitive pharmaceutical field. Growth plans will require hiring and training additional staff, increasing expenses.
• **Customers/Patients:** The development of novel pharmaceuticals for MASH and obesity aims to provide new treatment options. Success in clinical trials and regulatory approval could offer significant health benefits. However, undesirable side effects or lack of market acceptance could limit product availability.
• **Suppliers/Contractors:** Reliance on third-party CROs and manufacturers (especially Dong-A ST as the sole manufacturer for lead candidates) means their performance and compliance are critical to the company's development timelines and ability to commercialize products.
• **Creditors:** The 'going concern' warning indicates substantial doubt about the company's ability to meet its obligations in the normal course of business, posing a risk to creditors if additional financing is not secured.

Next Steps

• Finalize the Clinical Study Report (CSR) on the Phase 2a clinical trial for Vanoglipel (DA-1241) in the first half of 2026.
• Schedule an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) for Vanoglipel (DA-1241).
• Start Phase 1 Part 3a and Part 3b clinical trials for DA-1726 during the first quarter of 2026.
• Expect data readout for both DA-1726 Phase 1 Part 3a and Part 3b in the fourth quarter of 2026.
• Continue to explore out-licensing and divestiture opportunities for legacy therapeutic programs (ANA001, NB-01, NB-02, Gemcabene).
• Pursue additional pipelines and/or other business opportunities, including clinical-stage product candidates or other technologies.

Key Dates

Recommendation

MetaVia Inc. presents a high-risk, high-reward investment profile. The positive top-line clinical data for both Vanoglipel (DA-1241) in MASH and DA-1726 in obesity are significant and suggest strong therapeutic potential, which could drive future value. However, the company's severe financial condition, including recurring net losses, a substantial accumulated deficit, and an explicit 'going concern' warning, creates considerable uncertainty. While the current public offering aims to provide necessary capital, the long and expensive path to regulatory approval and commercialization, coupled with intense competition and potential for further dilution, warrants a cautious 'hold' recommendation. Investors should monitor the successful completion of the offering, subsequent clinical trial progress, and the company's ability to secure sustainable long-term funding.

Keywords

Biotechnology, Cardiometabolic diseases, MASH, Obesity, Type 2 Diabetes Mellitus, Vanoglipel, DA-1241, GPR119 agonist, DA-1726, Oxyntomodulin analog, GLP-1 receptor agonist, Glucagon receptor agonist, Clinical trials, Phase 2a, Phase 1, Public offering, Warrants, Common stock, Nasdaq, SEC filing, Biopharmaceutical, Drug development, Clinical-stage, Healthcare, Investment